983 1030
[21]
Paner GP, Amin MB, Alvarado-Cabrero I, et al. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol 2010;34:1233–40.[22]
Finley DS, Shuch B, Said JW, et al. The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma. J Urol 2011;186:2168–74.
[23]
Davis CF, Ricketts CJ, Wang M, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 2014;26:319–30.
[24]
Rathmell KW, Chen F, Creighton CJ. Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies. Oncoscience 2015;2:81–90.[25]
Chen YB, Xu J, Skanderup AJ, Dong Y. Molecular analysis of aggres- sive renal cell carcinoma with unclassified histology reveals dis- tinct subsets. Nat Commun 2016;7:13131.
[26]
Albiges L, Guegan J, Le Formal A, et al. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res 2014;20:3411–21.
[27]
Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal anti- bodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721–9.[28]
Burgess TL, Sun J, Meyer S, et al. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther 2010;9:400–9.
[29]
Schoffski P, Garcia JA, Stadler WM, et al. A phase II study of the efficacy and safety of AMG 102 in patients withmetastatic renal cell carcinoma. BJU Int 2011;108:679–86.[30]
Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9:1544–53.[31]
Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013;31: 181–6.
[32]
Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 2009;9:785–93.
[33]
Choueiri T, Plimack E, Arkenau H-T, et al. A single-arm biomarker- based phase II trial of savolitinib in patients with advanced papil- lary renal cell cancer (PRCC). J Clin Oncol 2017;35(suppl 6S), abstract 436.[34]
Garcia-Echeverria C, Sellers WR. Drug discovery approaches target- ing the PI3K/Akt pathway in cancer. Oncogene 2008;27:5511–26.
[35]
Voss MH, Molina AM, Chen YB, et al. Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. J Clin Oncol 2016;34: 3846–53.[36]
Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/ mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022–30.
[37]
Schnell CR, Stauffer F, Allegrini PR, et al. Effects of the dual phos- phatidylinositol 3-kinase/mammalian target of rapamycin inhibi- tor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008;68:6598–607.[38]
Carlo MI, Molina AM, Lakhman Y, et al. A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mam- malian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma. Oncologist 2016;21:787–8.[39]
Furge KA, Tan MH, Dykema K, et al. Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. On- cogene 2007;26:1346–50.
[40]
Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 2008;100: 1260–2.
[41]
Tan MH, Wong CF, Tan HL, et al. Genomic expression and single- nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer 2010;10:196.
[42]
Shuch B, Ricketts CJ, Vocke CD, et al. Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. J Urol 2013;190:1990–8.[43]
Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A 2006;103:15552–7.[44]
Baba M, Furihata M, Hong SB, et al. Kidney-targeted Birt-Hogg– Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008;100:140–54.[45]
Malouf GG, Ali SM, Wang K, et al. Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recur- rent genomic alterations. Eur Urol 2016;70:348–57.
[46]
Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014;46:225–33.[47]
Woodward ER, Ricketts C, Killick P, et al. Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN. Clin Cancer Res 2008; 14:5925–30.[48]
Vuky J, Fotoohy M, Isacson C, et al. Phase II trial of imatinib mesylate (formerly known as STI-571) in patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2003;22:abstr 1672.
[49]
Malouf GG, Su X, Yao H, et al. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing part- ners and frequent mutations of chromatin-remodeling genes. Clin Cancer Res 2014;20:4129–40.[50]
Argani P, Hicks J, De Marzo AM, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile empha- sizing novel RCC markers. Am J Surg Pathol 2010;34:1295–303.[51]
Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007;67:919–29.
[52]
Malouf GG, Monzon FA, Couturier J, et al. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res 2013;19:4673–84.
[53]
Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010;116:5219–25.
[54]
Malouf GG, Camparo P, Oudard S, et al. Targeted agents in meta- static Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 2010;21: 1834–8.[55]
Cost NG. RCC in adolescents and young adults (AYAs): diagnosis and management. Kidney Cancer Association 15th Kidney Cancer Symposium Miami FL November 2016.
[56]
Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Genitales) study. J Urol 2007;177:1698–702.[57]
Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20:2376–81.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 9 7 4 – 9 8 3
983